Previously known as Sensory Technologies Inc, Afferent Corporation is commercializing a breakthrough neurotherapy technology emerging from research at Boston University. Afferent's experienced management team has advanced the technology through an aggressive product development program. The Company's products will be used to treat sensory dysfunction resulting from disease and injury. Technology: Afferent's technology dramatically increases the flow of sensory information traveling from muscles, joints, and skin to the body's control centers. The Company's first products are targeted at restoring brain and motor function following stroke. By directly boosting sensory neural traffic from the extremities, Afferent's products will drive functional improvements that are unattainable using traditional therapies
